I personally own only one biotechnology stock.
Biotechnology popped on my radar when the thought of Donald Trump winning the presidency became a viable option.
His policies have cleared the way for businesses to advance with more assurance.
Within biotech, the personalized medicine segment is, by far, the fastest-growing niche, and the reason is that in a few years, it will be the only way patients will want to be treated.
Our top biotechnology company is armed with fully protected issued and pending patents across multiple nations and continents, it is led by top echelon scientific and business entrepreneurs, and it is already attracting the likes of pharmaceutical blue chip giants Johnson & Johnson and Merck to take interest.